Identity problem
TB-500 is often discussed like thymosin beta-4. It is not that simple.
A peptide fragment can be related to a larger biological peptide without inheriting every claim made about the original molecule.
Claim quality
Recovery marketing runs ahead of direct clinical evidence.
The online pitch often moves from cell migration and repair biology to confident injury outcomes without the clinical bridge that would make those claims strong.
Useful frame
Treat it as a claim audit, not a hype loop.
The most useful TB-500 page is not a protocol page. It is a map of what is known, what is borrowed from adjacent biology, and what remains unproven.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.